The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin
- 1 December 2021
- journal article
- research article
- Published by Elsevier in The Surgeon
- Vol. 19 (6) , e379-e385
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal CancerJournal of Clinical Oncology, 2011
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancerBritish Journal of Cancer, 2011
- Primary appendiceal carcinoma – Epidemiology, surgery and survival: Results of a German multi-center studyEuropean Journal of Surgical Oncology, 2010
- Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysisEuropean Journal of Cancer, 2009
- Classification of colorectal cancer based on correlation of clinical, morphological and molecular featuresHistopathology, 2006
- Systematic Review of Microsatellite Instability and Colorectal Cancer PrognosisJournal of Clinical Oncology, 2005
- Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for the Management of Peritoneal Carcinomatosis From Colorectal Cancer: A Multi-Institutional StudyJournal of Clinical Oncology, 2004
- Recurrences after Peritoneal Carcinomatosis of Colorectal Origin Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and OutcomeAnnals of Surgical Oncology, 2004
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Tumor Microsatellite Instability and Clinical Outcome in Young Patients with Colorectal CancerNew England Journal of Medicine, 2000